1. 201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC). (December 2022) Authors: Jerusalem, G.; De Braud, F.G.M.; de Jonge, M.J.A.; Grell, P.; Gonçalves, A.; Tan, T.J.Y.; Greil, R.; Yap, T.A.; Lin, C-C.; Kornbluth, K.A.; Yang, X.; Vong, C.; Choudhury, S.; Mataraza, J.; Lee, L.H.; Otero, J.A.; Garralda, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN BCMA-DIRECTED CAR-T CELL THERAPY MANUFACTURED USING THE T-CHARGETM PLATFORM FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM). (23rd June 2022) Authors: Sperling, A. S.; Nikiforow, S.; Derman, B.; Nadeem, O.; Mo, C.; Laubach, J.; Anderson, K.; Alonso, A.; Im, S.-Y.; Ikwgawa, S.; Prabhala, R.; Hernandez Rodriduez, D.; Daley, H.; Shaw, K. L.; Arihara, Y.; Ansari, S.; Quinn, D. S.; Pearson, D.; Hack, A.; Treanor, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗